|  
             Roswell Park Memorial Institute, Medical On cology, 
              666 elm Street, Buffalo, New York 14263, USA  
            Through the years considerable advances have been made, and have 
              been highly publicized in developing curative regimens for acute 
              lymphocytic leukemia. For most large series the probability of a 
              long-term continuous complete remission exceeds 0.5. Equally well 
              publicized have been the less dramatic, but steady advances in the 
              management of adult nonlymphocytic acute leukemias where long-term 
              survivals are reported in 10%-30% of cases, depending both on the 
              rigorousness of treatment and the constraints of eligibility to 
              the study. Surprisingly, relatively little attention has been afforded 
              the good news in the treatment of acute myelocytic leukemias occurring 
              in pediatric patients during this same period. Clearly a child with 
              AML has a harder row to hoe than does his counterpart with ALL. 
              At the same time a few single-institution studies have achieved 
              strikingly good results with these patients (Weinstein, Leventhal) 
              using aggressive chemotherapy, and a not incon.siderable proportion 
              of the successes of allogeneic bone marrow transplantation have 
              depended upon HLAmatched siblings of this younger age group. However, 
              only recently have large controlled trials been conducted and analyzed 
              which employed intensive chemotherapy in childhood AML. The studies 
              presented by Creutzig and her coworkers within the Berlin-Frankfurt-Miinster 
              group are notable examples of the signal advances in pediatric patient 
              management and the outstanding contributions made by West German 
              clinical investigators during the past decade. All students of leukemia 
              have been inspired by the early studies of the treatment of childhood 
              ALL, conducted by pathologists, internists, and even pediatricians 
              in those happy times when an ecumenical spirit of achievement held 
              sway. Today we continue to turn to advanced studies in childhood 
              cancers for those leads which may be used in hematological malignancies 
              of all age groups. 
               
              For these several reasons the poster presentation by Creutzig et 
              al. was chosen not only "best of class " but "best of show. "  
            Edward Henderson  
              T. A. Lister, K. A. McCreche  
              The poster awards selection committee  
           |